• No products in the cart.


Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Multiple Myeloma patients in sub-Saharan Africa.

Lead Faculty: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist

Executive Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: director@intercancer.com

Website: www.intercancer.com

This educational activity is provided by the International Cancer Institute (ICI)


  1. Prof. Riyat Malkit-Consultant Hematologist
  2. Dr. Anthony Betbadal- Adult Hematologist
  3. Dr. Hussein Elias- Palliative Care Specialist/Family Medicine
  4. Dr. Teresa Lotodo-Hematopathologist
  5. Mercy Oduor-Multiple Myeloma Pharmacovigilance
  6. Dr. Helena Musau-Clinical Oncologist
  7. Dr. Irene Weru-Oncology Pharmacist
  8. Dr. Collins Kirwa-Oncology Pharmacist

This course will be accredited by:

Accredited by KMPDB
Accredited by KMPDB


Accredited by KPPB
Accredited by KPPB
Accredited by COC
Accredited by COC






Target Audience

The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.


At the end of this educational activity, participants should be able to:

  1. At the end of this educational activity, participants should be able to:
  2. To learn about Multiple Myeloma outcome data in Kenya and sub-Saharan Africa (SSA)
  3. To discuss diagnostics, staging and evaluation of a multiple myeloma patient
  4. To understand the optimal therapies, trends, research and strategies designed to improve the quality of care in multiple myeloma including discussion on the role of Pharmacovigilance.
  5. To understand the role of the multidisciplinary team in multiple Myeloma management
  6. To understand the role of Palliative and supportive care in multiple Myeloma management
  7. Evaluate tools and resources for the management of multiple myeloma that can be used to achieve effective cancer care delivery and improve the patient experience in SSA
  8. To discuss clinical cases between faculty and participants
  9. To share experiences on How to set-up a Multiple Myeloma care program in SSA


Disclosure of Conflicts of Interest

International Cancer Institute (ICI) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labelled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit.

To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.

The Program


  1. Orientation to the course (Chite) Monday 18th May 2020 4:00-4:30 PM EAT
  2. Multiple Myeloma Data in Kenya and SSA (Chite). Wednesday 20th May 2020 4:00-5:30 PM EAT
  3. Plasma Dyscrasias, Evaluation, Diagnosis and Staging of Multiple Myeloma (Riyat). 25th May 2020 4:00-5:30 PM EAT
  4. The Role of Pathology in Multiple Myeloma (Lotodo). 27th May 2020 4:00-5:30 PM EAT
  5. Risk stratification, treatment of Multiple Myeloma & targeted therapies (Anthony). 1st June 2020 4:00-5:30 PM EAT
  6. Classification of Anti-neoplastic agents used in the treatment of Multiple Myeloma (Weru & Collins) 3rd June 2020 4:00-5:30 PM EAT
  7. Pharmacovigilance in the care of Multiple Myeloma patients (Mercy). 8th June 2020 4:00-5:30 PM EAT
  8. Role of stem-cell transplant in Multiple Myeloma (Anthony). 10th June 2020 4:00-5:30 PM EAT
  9. The Role of Radiotherapy in Multiple Myeloma Management (Helena). 15th June 2020 4:00-5:30 PM EAT
  10. Palliative and supportive care in multiple Myeloma management (Hussein). 17th June 2020 4:00-5:30 PM EAT
  11. Multiple Myeloma Clinical Cases by Faculty and Participants (Anthony & Chite). 22nd June 2020, 2020 4:00-5:30 PM EAT
  12. How to set-up a Multiple Myeloma Program in SSA (Chite). 24th June 2020 4:00-5:30 PM EAT


Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 24 hours)

All those interested in registration to this course, please send your information to info@intercancer.com


ICI Acknowledges that the funding for this preceptorship training has been proudly supported by the Bristol-Myers Squibb Foundation (BMSF) Secure the Future Programme.




Course Reviews


2 ratings
  • 5 stars2
  • 4 stars0
  • 3 stars0
  • 2 stars0
  • 1 stars0
  1. The Role of Pathology in Multiple Myeloma


    Teresa Lotodo gave a good introduction to this lecture by defining MM and other plasma dyscrasias. She dwelt on diagnosis, risk stratification, staging and monitoring of MM.

    Of interest to me was her discourse on IHC and FISH. The use of CD markers to identify the clonality of the abnormal plasma cells.

    She also discussed bone marrow aspiration, indications, possible sites, processing of tissues, preparation of slides and reading of the slides by pathologists.
    There were pictures and charts to aid understanding of her lectures.

    It was well delivered and I learnt a lot.

    Thank you.

  2. My Experience With The ICI Multiple Myeloma Preceptorship


    It was a great experience joining with the various faculties these 6 weeks.
    The course was all encompassing – a great example of team work in medicine. The course involved all aspects of myeloma care. As an experienced haematologist with several years of practice, I still found the course very useful and relevant to my practice.
    The faculties were great . They made the classes very interesting by making every session interactive.
    I do hope to foster both clinical and research relationships with my classmates
    Many thanks to the director and the entire faculty
    Omolade Awodu

© 2022 International Cancer Institute. All Rights Reserved